You are here

  • Home
  • Archive
  • Volume 60, Issue 4
  • A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study

Article Text

Article menu
Download PDFPDF
Concise report
A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study
  1. H Schmelinga,
  2. K Mathonya,
  3. V Johna,
  4. G Keyβerb,
  5. St Burdacha,
  6. G Horneffa
  1. aDepartment of Paediatrics, Martin-Luther University Halle-Wittenberg, Halle, Germany, bDepartment of Medicine I
  1. Dr Horneff, Department of Paediatrics, Martin-Luther University Halle-Wittenberg, 06120 Halle, Germanygerd.horneff{at}medizin.uni-halle.de

Abstract

OBJECTIVE To study the efficacy of combination therapy with etanercept and methotrexate in patients with refractory juvenile idiopathic arthritis.

METHODS Seven children with active juvenile idiopathic arthritis refractory to at least combination therapy with methotrexate and sulfasalazine or cyclosporin A were studied. Concomitant treatment, consisting of non-steroidal drugs, corticosteroids, and methotrexate, remained unchanged.

RESULTS Six patients continued the treatment for at least 24 weeks. In the child with systemic arthritis, etanercept was stopped because of persisting spiking fever, joint pain, and rash. In the remaining children an immediate significant decrease in joint pain (p<0.05), disappearance of morning stiffness, and regression of joint swelling (p<0.05) were observed. Improvement was apparent after two injections. An immediate significant (p<0.05) decrease in erythrocyte sedimentation rate, C reactive protein, and interleukin 6 was observed. Side effects consisted of mild reactions at the injection site in two children.

CONCLUSIONS In this observational study, etanercept in combination with methotrexate was well tolerated and highly effective in treating juvenile polyarthritis but not in the patient with systemic arthritis. Combination treatment appears to be feasible in terms of toxicity and may enhance efficiency.

  • juvenile arthritis
  • etanercept
  • tumour necrosis factor α
  • methotrexate

https://doi.org/10.1136/ard.60.4.410

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text